“Secukinumab Treatment in Radiographic Axial Spondyloarthritis Patients: Low Spinal Progression and Mineralization Marker Decrease in Clinical Practice”

https://pubmed.ncbi.nlm.nih.gov/38115870

Two years of secukinumab treatment in patients with radiographic axial spondyloarthritis in daily clinical practice showed low radiographic spinal progression, stable collagen resorption and formation markers, and a significant decrease in mineralization marker BALP.